3D bioprinting technology capable of creating living human tissue cells on demand Their mission is to improve the predictive accuracy of pre-clinical drugs by providing pharmaceutical companies and researchers with 3D human tissue they can to test new therapeutics. In the long term this can lead to full organ printing. Bottom line - Aspect’s technology has the potential to drive a fundamental shift in the pharmaceutical industry by speeding the time it takes companies release new drugs. Potential to reduce the use of laboratory animals and waste involved with new drugs productions. The Bioprinting space is heating up with new companies testing printed blood and other life science breakthroughs.
A New Approach to 3D Printing Removes the Limitations of Gravity
The potential for 3D printing to revolutionize manufacturing is astounding—if the technology can overcome a few limitations. Researchers at MIT’s Self-Assembly Lab have come up with a novel way to both speed up the 3D printing process, and free it from the restrictions imposed by gravity.
Boeing uses first FAA-approved 3D-printed parts for the 787
Boeing expects to shave $2 to $3 million off each 787 Dreamliner's manufacturing costs by 2018, thanks to 3D-printed titanium. The company has teamed up with No...